Abivax to Present Results of Trials of ABX464 as Ulcerative Colitis Therapy

Abivax to Present Results of Trials of ABX464 as Ulcerative Colitis Therapy
Abivax will present the complete results of its Phase 2a trial ABX464-101 (NCT03093259) and interim results of the open-label extension study ABX464-102 (NCT03368118). Both aimed to assess the safety and efficacy of ABX464 as a treatment for ulcerative colitis. The data will be presented at the 14thCongress of the European Crohn’s and Colitis Organization (ECCO) March 6-9 in Copenhagen, Denmark. The oral presentation is titled "
Subscribe or to access all post and page content.